Re-defining clinically
applicable genomic
analysis
The realisation of clinically applicable next-generation sequencing solutions represents one of today’s greatest technology challenges.
The potential benefits are enormous, ushering in diagnosis that is faster, more accurate, requiring less DNA and cheaper than traditional methods. But the scale of the challenge is significant
DNAe is a pioneer in this vital field. For more than 10-years, the company has applied its expertise in diagnostic and semiconductor technologies to bring innovative, life-saving benefits to patients. DNAe is taking DNA sequencing from specialised genome centres into hospitals, the clinic and the point of care.
Today, this award-winning company is a highly specialised team of 125 professionals based in London and Carlsbad, California. Spun out of Imperial College, the company is developing its DNA sequencing platform for the rapid diagnosis of infectious diseases and anti-biotic resistance.
The Deep Tech Leaders team has worked closely with DNAe since 2015 and recruited several key appointments. Recently, we have appointed their VP of Commercial – Alison Howie (ex-Ixico & Thermo Fisher), VP of Technology – Richard Hammond (ex- Cambridge Consultants & Alere) and Head of Operations – Fraser Matthews (ex-GSK).”
